Complement activation in patients with neuromyelitis optica
The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a...
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
Elsevier
2014
|
| _version_ | 1826266495156486144 |
|---|---|
| author | Nytrova, P Potlukova, E Kemlink, D Woodhall, M Horakova, D Waters, P Havrdova, E Zivorova, D Vincent, A Trendelenburg, M |
| author_facet | Nytrova, P Potlukova, E Kemlink, D Woodhall, M Horakova, D Waters, P Havrdova, E Zivorova, D Vincent, A Trendelenburg, M |
| author_sort | Nytrova, P |
| collection | OXFORD |
| description | The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a and soluble C5b-9 in patients with NMO, multiple sclerosis and healthy controls. NMO patients had higher levels of C3a and anti-C1q antibodies than healthy controls. C3a levels correlated with disease activity, neurological disability and aquaporin-4 IgG in NMO patients suggesting a role of the alternative pathway of complement in the pathogenesis of NMO and supporting the strategy of therapeutic complement inhibition. © 2014 Elsevier B.V. |
| first_indexed | 2024-03-06T20:39:49Z |
| format | Journal article |
| id | oxford-uuid:33e43cdc-f9bd-465b-b869-d56b1250bfe2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:39:49Z |
| publishDate | 2014 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:33e43cdc-f9bd-465b-b869-d56b1250bfe22022-03-26T13:22:47ZComplement activation in patients with neuromyelitis opticaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:33e43cdc-f9bd-465b-b869-d56b1250bfe2EnglishSymplectic Elements at OxfordElsevier2014Nytrova, PPotlukova, EKemlink, DWoodhall, MHorakova, DWaters, PHavrdova, EZivorova, DVincent, ATrendelenburg, MThe role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a and soluble C5b-9 in patients with NMO, multiple sclerosis and healthy controls. NMO patients had higher levels of C3a and anti-C1q antibodies than healthy controls. C3a levels correlated with disease activity, neurological disability and aquaporin-4 IgG in NMO patients suggesting a role of the alternative pathway of complement in the pathogenesis of NMO and supporting the strategy of therapeutic complement inhibition. © 2014 Elsevier B.V. |
| spellingShingle | Nytrova, P Potlukova, E Kemlink, D Woodhall, M Horakova, D Waters, P Havrdova, E Zivorova, D Vincent, A Trendelenburg, M Complement activation in patients with neuromyelitis optica |
| title | Complement activation in patients with neuromyelitis optica |
| title_full | Complement activation in patients with neuromyelitis optica |
| title_fullStr | Complement activation in patients with neuromyelitis optica |
| title_full_unstemmed | Complement activation in patients with neuromyelitis optica |
| title_short | Complement activation in patients with neuromyelitis optica |
| title_sort | complement activation in patients with neuromyelitis optica |
| work_keys_str_mv | AT nytrovap complementactivationinpatientswithneuromyelitisoptica AT potlukovae complementactivationinpatientswithneuromyelitisoptica AT kemlinkd complementactivationinpatientswithneuromyelitisoptica AT woodhallm complementactivationinpatientswithneuromyelitisoptica AT horakovad complementactivationinpatientswithneuromyelitisoptica AT watersp complementactivationinpatientswithneuromyelitisoptica AT havrdovae complementactivationinpatientswithneuromyelitisoptica AT zivorovad complementactivationinpatientswithneuromyelitisoptica AT vincenta complementactivationinpatientswithneuromyelitisoptica AT trendelenburgm complementactivationinpatientswithneuromyelitisoptica |